Loading
Diabetes Treatment and Management / Gastric Cancer Management and Outcomes · Journal article
American Journal of Clinical Oncology · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This single-center retrospective study of 200 patients receiving concurrent GLP-1 RA and platinum chemotherapy reports that 63% (126/200) developed upper GI adverse events, predominantly managed with 5-HT3 antagonists, with 92.7% achieving clinical remission. The lack of a concurrent control group and retrospective design prevent definitive attribution of GI toxicity to GLP-1 RA versus platinum chemotherapy alone or their interaction.
Single-center retrospective cohort study. Patients with cancer receiving concurrent platinum-based chemotherapy and GLP-1 receptor agonists (for type 2 diabetes or obesity management) who developed upper GI adverse event symptoms, treated at a single center. Intervention: GLP-1 receptor agonist concurrent with platinum-based chemotherapy. Compared with: Within-cohort comparison: patients with GI AE versus patients without GI AE (no external control arm). n = 200. Single center (location not specified in text).
Upper GI adverse events occurred in 126 of 200 patients (63%) Patients with GI AE received fewer platinum doses (median 2.5 vs 5, P <0.0001) and had higher all-cause mortality (40.5% vs 25.7%, P=0.034) GI AE treated with 5-HT3 antagonists in 123 patients (99.2%); median symptom duration 42.5 days with 92.7% clinical remission
Retrospective design subject to selection bias and incomplete ascertainment of adverse events Higher mortality and reduced platinum dosing in GI AE group may reflect disease severity or performance status confounding rather than causal effect of GI AE itself
Clinicians managing patients on concurrent GLP-1 RA and platinum chemotherapy should anticipate a high incidence of upper GI adverse events (63%), most responsive to standard antiemetic therapy with 5-HT3 antagonists. However, the lack of a control arm limits understanding of whether GLP-1 RA itself increases GI toxicity beyond platinum chemotherapy alone, and the higher mortality and fewer completed doses in the GI AE group warrant investigation into whether GI adverse events are a marker of severity or a direct contributor to worse outcomes.
Single-center retrospective study without a control arm comparing GLP-1 RA users to non-users; observational design with potential confounding limits causal inference about GLP-1 RA's specific role in GI adverse events during platinum chemotherapy.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians managing patients on concurrent GLP-1 RA and platinum chemotherapy should anticipate a high incidence of upper GI adverse events (63%), most responsive to standard antiemetic therapy with 5-HT3 antagonists. However, the lack of a control arm limits understanding of whether GLP-1 RA itself increases GI toxicity beyond platinum chemotherapy alone, and the higher mortality and fewer completed doses in the GI AE group warrant investigation into whether GI adverse events are a marker of severity or a direct contributor to worse outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objectives: Many patients with cancer receive chemotherapy alongside glucagon-like peptide-1 receptor agonists (GLP-1 RA) to manage type 2 diabetes or obesity. However, both GLP-1 RA and platinum-based chemotherapies can cause upper gastrointestinal (GI) adverse effects (AE) such as nausea and vomiting. This study aimed to evaluate the impact of GLP-1 RA use in patients receiving platinum-based chemotherapy, focusing on GI AE incidence, risk factors, and treatment outcomes. Methods: This single-center study retrospectively reviewed patients who were treated with a platinum-based therapy and concurrent GLP-1 RA and developed symptoms of upper GI AE. Results: The study included 200 patients. Upper GI adverse events occurred in 126 patients. Compared with patients without GI AE, patients with GI AE received fewer doses of platinum therapy (median: 2.5 vs. 5, P <0.0001) and had higher all-cause mortality (40.5% vs. 25.7%, P =0.034), shorter follow-up (median: 1.5 vs. 2.7 y, P <0.0001), and a higher rate of hypothyroidism (35.1% vs. 20.6%, P =0.025). GI AEs were treated with 5-HT3 receptor antagonists in 123 (99.2%) patients and corticosteroids in 5 (4.0%). GI AE symptoms lasted a median of 42.5 days; 92.7% achieved clinical remission of GI AE. Twenty-one (16.7%) patients required hospitalization for GI AE, of whom 4 required rehospitalization. Platinum analogs were discontinued in 72 (57.1%) patients and resumed in 57 (79.2%). GLP-1 RA was discontinued in 11 (8.7%) patients. Conclusions: Most patients receiving GLP-1 RA and platinum-based chemotherapy developed mild GI AE that responded to conservative management.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.